Daiichi Sankyo Co. Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Savaysa (edoxaban) tablets, an oral, once-daily selective factor Xa-inhibitor, to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF).

Lithoplasty is a balloon-based technology that utilizes integrated lithotripsy to disrupt both superficial and deep calcium and normalize vessel wall compliance prior to low-pressure balloon dilatation.

ECRI Institute’s 2015 Top 10 Hospital C-Suite Watch List, available as a free public service, answers key questions on new and emerging health technologies that potentially provide new ways to treat patients, improve care and reduce costs.

CardioFocus Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation (AF), announced that it has executed an exclusive, multi-year distribution agreement with Japan Lifeline Co. Ltd.

Transcatheter Technologies GmbH has announced that it is expanding its product family to include Tresillo, a transcatheter mitral valve implantation (TMVI) version. 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now